Impact of Mortality Salience on Treatment Decisions

Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how the awareness of mortality, or the realization that life is limited, affects treatment decisions made by both urologists and patients with urological cancer. The researchers want to find out if this awareness leads to more aggressive treatment choices, meaning treatments that are more intense or invasive. They’ll also look at whether certain factors can predict these decisions and if a specific questionnaire can effectively measure the fear of cancer progression in patients.

If you’re a urologist or a patient with urological cancer and meet the eligibility criteria, you may be able to participate. For urologists, you need to have good cognitive ability and speak German. For patients, you must be at least 18 years old, have a diagnosis of urological cancer, and also speak German. Participants will complete a survey designed to trigger thoughts about mortality and will respond to case scenarios about treatment options. The study is currently recruiting participants, and there are no specific exclusions, making it an inclusive opportunity for those who qualify.

Gender

ALL

Eligibility criteria

• • Study 1) Urologists
• Inclusion Criteria:
• • sufficient cognitive ability
• • German language skills
• Exclusion Criteria:
• • none
• • Study 2) Patients
• Inclusion Criteria:
• • urological cancer (ICD-10: C60, C61, C62, C63, C64, C65, C66, C67, C68)
• • age at least 18 years
• • German language skills
• • sufficient cognitive ability
• • capacity to consent
• Exclusion Criteria:
• • none